Biofoundry Services News Today

Telesis Bio Reports Fourth Quarter and Full Year 2023 Financial Results GlobeNewswire March 28, 2024 SAN DIEGO, March 28, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ: TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, flexible, and rapid automated synthesis in their own...

Telesis Bio, Inc. (NASDAQ:DNAY – Get Rating)’s share price traded up 0.7% on Thursday . The stock traded as high as $2.92 and last traded at $2.88. 59,993 shares were traded during trading, an increase of 11% from the average session volume of 54,063 shares. The stock had previously closed at $2.86. Telesis Bio Price […]

Telesis Bio, Inc. (NASDAQ:DNAY – Get Rating) dropped 8.4% during trading on Wednesday . The stock traded as low as $2.64 and last traded at $2.73. Approximately 66,821 shares traded hands during mid-day trading, an increase of 24% from the average daily volume of 54,063 shares. The stock had previously closed at $2.98. Telesis Bio […]

Should You Buy or Sell Telesis Bio Stock? Get The Latest DNAY Stock Forecast, Price Target, Earnings Estimates, Headlines, Short Interest at MarketBeat.

Telesis Bio, Inc. (NASDAQ:DNAY – Get Rating) shares fell 4.2% on Tuesday . The stock traded as low as $2.51 and last traded at $2.76. 232,448 shares were traded during trading, an increase of 330% from the average session volume of 54,063 shares. The stock had previously closed at $2.88. Telesis Bio Trading Up 0.7 […]

SeqLL (NASDAQ:SQL – Get Rating) and Codex DNA (NASDAQ:DNAY – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, risk, dividends and institutional ownership. Profitability This table compares SeqLL and Codex DNA’s net margins, […]

Codex DNA (NASDAQ:DNAY – Get Rating) is one of 42 public companies in the “Analytical instruments” industry, but how does it weigh in compared to its rivals? We will compare Codex DNA to related businesses based on the strength of its risk, valuation, profitability, institutional ownership, dividends, earnings and analyst recommendations. Institutional & Insider Ownership […]

Codex DNA (NASDAQ:DNAY – Get Rating) is one of 42 public companies in the “Analytical instruments” industry, but how does it contrast to its competitors? We will compare Codex DNA to related businesses based on the strength of its earnings, dividends, institutional ownership, profitability, risk, valuation and analyst recommendations. Profitability This table compares Codex DNA […]

Codex DNA (NASDAQ:DNAY – Get Rating) is one of 43 public companies in the “Analytical instruments” industry, but how does it compare to its rivals? We will compare Codex DNA to similar companies based on the strength of its profitability, institutional ownership, valuation, dividends, risk, earnings and analyst recommendations. Profitability This table compares Codex DNA […]

Codex DNA (NASDAQ:DNAY – Get Rating) is one of 43 publicly-traded companies in the “Analytical instruments” industry, but how does it contrast to its peers? We will compare Codex DNA to similar companies based on the strength of its earnings, risk, institutional ownership, dividends, profitability, analyst recommendations and valuation. Institutional & Insider Ownership 87.6% of […]